ClinicalTrials.gg
RecruitingNCT05474430Updated Sep 4, 2026

Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity

An observational study in Carrier State and Respiratory Infections, sponsored by Philip Polgreen. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Philip Polgreen · Observational

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
160
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Respiratory Tract Infections with a site in United States — 20 open to participants now, 28 under way, 5 of them phase 3. Respiratory Tract Infections · United States.

Planned enrollment
35th of 48
160 · median 558
Started
2021
with 5 others
Observational
48 of 210
4 open now
Primary completion
2026-12
later than 6 of 26 live
Registered
168th of 210
by date

Among the 210 studies in Respiratory Tract Infections with a site in United States, this one is the 35th largest by planned enrollment of the 48 observational ones that give a count, is one of 6 that started in 2021, is one of 48 observational ones, reaches primary completion later than 6 of the 26 other live ones, and was the 168th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

20 of the 210 studies in Respiratory Tract Infections with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Respiratory Tract Infections with a site in United States, or all of them as a file.
02

Study summary

A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays.

An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19.

The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.

03

Conditions studied

  • Carrier State
  • Respiratory Infections
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

CF Carriers and Controls who are not CF carriers.

Eligibility criteria

CF Carrier Inclusion Criteria:

  • Previously tested and shown to be a CF carrier
  • English-speaking

Control Group Inclusion Criteria:

  • Previously tested and shown to not be a CF carrier or CF patient
  • English-speaking

Exclusion Criteria:

  • Currently sick with a respiratory infection
  • Prisoner Status
  • Unable to provide own written,
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
160 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cystic Fibrosis Carrier Group

    Participants have been identified as Cystic Fibrosis Carriers via previous genetic testing.

  • Control Group

    Participants have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.

06

What researchers measure

Primary outcomes

  1. Comparison of Chloride Transport Values

    Comparison of chloride transport values in cystic fibrosis carrier group vs control group via t-test.

    Time frame: At baseline

  2. Comparison of Bicarbonate Transport Values

    Comparison of bicarbonate transport values in cystic fibrosis carrier group vs control group via t-test.

    Time frame: At baseline

  3. Comparison of Airway Surface Liquid pH Values

    Comparison of airway surface liquid pH values in cystic fibrosis carrier group vs control group via t-test.

    Time frame: At baseline

  4. Comparison of Mucous Viscosity Values

    Comparison of mucous viscosity values in cystic fibrosis carrier group vs control group via t-test.

    Time frame: At baseline

  5. Comparison of Bacterial Killing Values

    Comparison of bacterial killing values in cystic fibrosis carrier group vs control group via t-test.

    Time frame: At baseline

Secondary outcomes

  1. Comparison of Fibroblast Growth Factor-19 Values

    Comparison of fibroblast growth factor-19 values in cystic fibrosis carrier group vs control group via t-test.

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2022
First posted
Jul 26, 2022
StartActual
Dec 20, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05474430
Lead sponsor
Philip Polgreen
Responsible party
Philip Polgreen (Professor, Internal Medicine, University of Iowa) — Sponsor-investigator
First posted
Jul 26, 2022
Start date
Dec 20, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 4, 2026

Study contacts

Philip M Polgreen, MD
Contact
philip-polgreen@uiowa.edu
(319) 384-6194
Shelby L Francis, PhD
Contact
shelby-francis@uiowa.edu
319-678-8037
Philip M Polgreen, MD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion